

Edgar Filing: COATES C ROBERT - Form DFAN14A

COATES C ROBERT
Form DFAN14A
September 12, 2002

=====

SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934

Filed by the Registrant []
Filed by a Party other than the Registrant [X]

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Under Rule 14a-12

NORTHFIELD LABORATORIES INC.

(Name of Registrant as Specified in its Charter)

C. ROBERT COATES

(Name of Person(s) Filing Proxy Statement if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- \$125 per Exchange Act Rules 0-11(c)(1)(ii), 14a-6(i)(1), 14a-6(i)(2) or Item 22(a)(2) of Schedule 14A.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 - 1) Title of each class of securities to which transaction applies:
 - 2) Aggregate number of securities to which transaction applies:
 - 3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
 - 4) Proposed maximum aggregate value of transaction:
 - 5) Total fee paid:
- Fee paid previously with preliminary materials.
- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 - 1) Amount Previously Paid:
 - 2) Form, Schedule or Registration Statement No.:
 - 3) Filing Party: C. Robert Coates
 - 4) Date Filed: September 12, 2002

=====

Press Release

Edgar Filing: COATES C ROBERT - Form DFAN14A

SOURCE: C. Robert Coates

COATES, WILLIAMS TELL SHAREHOLDERS: ELECT US AND WE WILL SUPPORT BIERBAUM, NESS

LAKE FOREST, Ill., Sept. 12 -- C. Robert Coates and Bert Williams, independent candidates for directorships of Northfield Laboratories (Nasdaq: NFLD), reiterated their "no-lose" proposition for shareholders: elect them to the board and still benefit from the services of John F. Bierbaum and Dr. Paul M. Ness, the two Northfield-endorsed nominees.

"Our first intention if we win the September 13 election is to expand the board by adding Bierbaum and Ness, a move expressly allowed by Northfield's bylaws", said Coates.

Coates holds a 4.5% stake in Northfield and has a background in finance and management; Williams has extensive management, marketing and Food and Drug Administration experience. Bierbaum is an executive of PepsiAmericas Inc., which holds 10.5% of Northfield's stock and is its largest shareholder, while Ness is a professor of pathology at Johns Hopkins University.

"Northfield has spent an enormous sum of time and money on this proxy contest, resources that might more wisely have gone toward getting approval of its stalled PolyHeme blood substitute", said Coates.

"The company also has issued numerous press releases. We are happy to see them starting to communicate with investors, but we find the information they put out contains little of substance. Shareholders still have no clear understanding of where Northfield is in the FDA process or how long the company can survive without getting PolyHeme approved", Coates added.

As shareholder advocates, Coates and Williams have vowed to keep investors informed of Northfield news, something that will be much easier with direct access to information on the board of directors. They also will work with directors and management to advance Northfield's efforts in finding a major pharmaceutical company to invest money and talent in Northfield and in advancing PolyHeme to commercialization. Their goal remains to improve performance of the company's underperforming shares in the market.

Contact Information

If you are a shareholder with comments, suggestions or questions about the Sept. 13 proxy contest, please call Simon Goldberg of the Robert Coates Group at 1-800-295-0841, extension 240, or e-mail us at sgoldberg@rcoates.com.

SOURCE: C. Robert Coates

right-width: 0; border-left-width: 0; border-bottom-width: 1"> 09/23/2010**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- The option grant was approved by the compensation committee of the board of directors of Soligenix, Inc. (the "Company") on July 1, 2010, subject to stockholder approval of an amendment to the Company's 2005 Equity Incentive Plan (the "Plan") to increase the
- (1) maximum number of shares of common stock available for issuance under the Plan. The Company's stockholders approved the amendment to the Plan on September 23, 2010. The stock option vested as to 200,000 shares on July 1, 2010 with the remainder vesting quarterly in equal amounts on each three (3) month anniversary of July 1, 2010 for the next three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Edgar Filing: COATES C ROBERT - Form DFAN14A

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.